Perspective Therapeutics (CATX) 10-Q 13 May 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2020	May 11, 2020
Document Information [Line Items]
Entity Registrant Name	IsoRay, Inc.
Entity Central Index Key	0000728387
Trading Symbol	isr
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		67,650,547
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common stock, $0.001

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Jun. 30, 2019
Current assets:
Cash and cash equivalents	$ 2,405	$ 5,326
Accounts receivable, net	2,147	1,154
Inventory	580	530
Prepaid expenses and other current assets	587	305
Total current assets	5,719	7,315
Property and equipment, net	1,744	1,609
Right of use asset, net (Note 8)	1,059
Restricted cash	181	181
Inventory, non-current	126	155
Other assets, net of accumulated amortization	133	162
Total assets	8,962	9,422
Current liabilities:
Accounts payable and accrued expenses	937	683
Lease liability (Note 8)	232
Accrued protocol expense	45	133
Accrued radioactive waste disposal	87	74
Accrued payroll and related taxes	260	89
Accrued vacation	183	142
Total current liabilities	1,744	1,121
Long-term liabilities:
Non-current Lease Liability	830
Asset retirement obligation	570	621
Total liabilities	3,144	1,742
Commitments and contingencies (Note 7)
Shareholders' equity:
Common stock, $.001 par value; 200,000,000 shares authorized; 67,650,547 and 67,388,047 shares issued and outstanding	68	67
Additional paid-in capital	92,500	92,105
Accumulated deficit	(86,750)	(84,492)
Total shareholders' equity	5,818	7,680
Total liabilities and shareholders' equity	8,962	9,422
Series B Preferred Stock [Member]
Shareholders' equity:
Preferred stock

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2020	Jun. 30, 2019
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	7,000,000	7,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	67,650,547	67,388,047
Common stock, shares outstanding (in shares)	67,650,547	67,388,047
Series B Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	59,065	59,065
Preferred stock, shares outstanding (in shares)	59,065	59,065

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Sales, net	$ 2,880,000	$ 1,924,000	$ 7,401,000	$ 5,390,000
Cost of sales	1,174,000	1,045,000	3,348,000	3,222,000
Gross profit	1,706,000	879,000	4,053,000	2,168,000
Research and development:
Proprietary research and development	294,000	299,000	804,000	1,088,000
Collaboration arrangement, net of reimbursement				45,000
Total research and development	294,000	299,000	804,000	1,133,000
Sales and marketing	805,000	645,000	2,286,000	1,996,000
Gain on equipment disposal		(1,000)		(24,000)
General and administrative	1,155,000	1,099,000	3,323,000	3,173,000
Gain on change in estimate of asset retirement obligation			(73,000)
Total operating expenses	2,254,000	2,042,000	6,340,000	6,278,000
Operating loss	(548,000)	(1,163,000)	(2,287,000)	(4,110,000)
Non-operating income:
Interest income, net	3,000	34,000	29,000	59,000
Other income		2,000		2,000
Non-operating income	3,000	36,000	29,000	61,000
Net loss	(545,000)	(1,127,000)	(2,258,000)	(4,049,000)
Preferred stock dividends	(3,000)	(3,000)	(8,000)	(8,000)
Net loss applicable to common shareholders	$ (548,000)	$ (1,130,000)	$ (2,266,000)	$ (4,057,000)
Basic and diluted loss per share (in dollars per share)	$ (0.01)	$ (0.02)	$ (0.03)	$ (0.06)
Weighted average shares used in computing net loss per share:
Basic and diluted (in shares)	67,558	67,333	67,444	66,937

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,258,000)	$ (4,049,000)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation expense	113,000	100,000
Gain on equipment disposals		(24,000)
Amortization of other assets	29,000	37,000
Accretion of asset retirement obligation	22,000	23,000
Gain on change in ARO estimate due to lease modification	(73,000)
Share-based compensation	276,000	269,000
Changes in operating assets and liabilities:
Accounts receivable, net	(993,000)	76,000
Inventory	(21,000)	37,000
Prepaid expenses and other current assets	(283,000)	(53,000)
Accounts payable and accrued expenses	258,000	(390,000)
Accrued protocol expense	(88,000)	40,000
Accrued radioactive waste disposal	13,000	28,000
Accrued payroll and related taxes	171,000	(117,000)
Accrued vacation	41,000	(41,000)
Net cash used by operating activities	(2,793,000)	(4,064,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(248,000)	(353,000)
Proceeds from sale of equipment		24,000
Proceeds from maturity of certificates of deposit		9,632,000
Purchases of and interest from certificates of deposit and U.S. Treasury securities		(11,141,000)
Net cash used by investing activities	(248,000)	(1,838,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid	(11,000)	(11,000)
Proceeds from sales of common stock, pursuant to registered direct offering, net		7,370,000
Proceeds from sales of common stock, pursuant to exercise of options	131,000	2,000
Net cash provided by financing activities	120,000	7,361,000
Net increase (decrease) in cash, cash equivalents, and restricted cash	(2,921,000)	1,459,000
Cash, cash equivalents, and restricted cash beginning of period	5,507,000	2,781,000
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF PERIOD	2,586,000	4,240,000
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	2,405,000	4,059,000
Restricted cash	181,000	181,000
Total cash, cash equivalents, and restricted cash	2,586,000	4,240,000
Non-cash investing and financing activities:
Recognition of operating lease liability and right of use asset	1,228,000
Warrants issued to placement agent of registered direct offering		$ 163,000

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Jun. 30, 2018	59,065	56,331,147
Balances at Jun. 30, 2018		$ 56	$ 84,322	$ (79,348)	$ 5,030
Issuance of common stock pursuant to registered direct offering, net (in shares)		11,000,000
Issuance of common stock pursuant to registered direct offering, net		$ 11	7,483		7,494
Share-based compensation			93		93
Net loss				(1,508)	(1,508)
Share-based compensation			93		93
Balances (in shares) at Sep. 30, 2018	59,065	67,331,147
Balances at Sep. 30, 2018		$ 67	91,898	(80,856)	11,109
Balances (in shares) at Jun. 30, 2018	59,065	56,331,147
Balances at Jun. 30, 2018		$ 56	84,322	(79,348)	5,030
Net loss					$ (4,049)
Issuance of common stock pursuant to exercise of options (in shares)					6,900
Balances (in shares) at Mar. 31, 2019	59,065	67,338,047
Balances at Mar. 31, 2019		$ 67	91,941	(83,397)	$ 8,611
Balances (in shares) at Sep. 30, 2018	59,065	67,331,147
Balances at Sep. 30, 2018		$ 67	91,898	(80,856)	11,109
Share-based compensation			97		97
Net loss				(1,414)	(1,414)
Offering costs pursuant to registered direct offering, net			(116)		(116)
Payment of dividend to preferred shareholders			(11)		(11)
Share-based compensation			97		97
Balances (in shares) at Dec. 31, 2018	59,065	67,331,147
Balances at Dec. 31, 2018		$ 67	91,868	(82,270)	9,665
Share-based compensation			79		79
Net loss				(1,127)	(1,127)
Offering costs pursuant to registered direct offering, net			(8)		$ (8)
Issuance of common stock pursuant to exercise of options (in shares)		6,900			6,900
Issuance of common stock pursuant to exercise of options			2		$ 2
Share-based compensation			79		79
Balances (in shares) at Mar. 31, 2019	59,065	67,338,047
Balances at Mar. 31, 2019		$ 67	91,941	(83,397)	8,611
Balances (in shares) at Jun. 30, 2019	59,065	67,388,047
Balances at Jun. 30, 2019		$ 67	92,105	(84,492)	7,680
Share-based compensation			91		91
Net loss				(816)	(816)
Share-based compensation			91		91
Balances (in shares) at Sep. 30, 2019	59,065	67,388,047
Balances at Sep. 30, 2019		$ 67	92,196	(85,308)	6,955
Balances (in shares) at Jun. 30, 2019	59,065	67,388,047
Balances at Jun. 30, 2019		$ 67	92,105	(84,492)	7,680
Net loss					$ (2,258)
Issuance of common stock pursuant to exercise of options (in shares)					262,500
Balances (in shares) at Mar. 31, 2020	59,065	67,650,547
Balances at Mar. 31, 2020		$ 68	92,500	(86,750)	$ 5,818
Balances (in shares) at Sep. 30, 2019	59,065	67,388,047
Balances at Sep. 30, 2019		$ 67	92,196	(85,308)	6,955
Share-based compensation			94		94
Net loss				(897)	(897)
Payment of dividend to preferred shareholders			(11)		(11)
Share-based compensation			94		94
Balances (in shares) at Dec. 31, 2019	59,065	67,388,047
Balances at Dec. 31, 2019		$ 67	92,279	(86,205)	6,141
Share-based compensation			91		91
Net loss				(545)	$ (545)
Issuance of common stock pursuant to exercise of options (in shares)		262,500			262,500
Issuance of common stock pursuant to exercise of options		$ 1	130		$ 131
Share-based compensation			91		91
Balances (in shares) at Mar. 31, 2020	59,065	67,650,547
Balances at Mar. 31, 2020		$ 68	$ 92,500	$ (86,750)	$ 5,818

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	9 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Basis of Presentation The accompanying unaudited interim consolidated financial statements are those of Isoray, Inc., and its wholly-owned subsidiaries, referred to herein as “Isoray” or the “Company”. All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form 10 June 30, 2019. The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not Certain prior period amounts have been reclassified to conform to the current period’s presentation. The results of operations for the periods presented may not may 2020 0%.

Note 2 - New Accounting Standar

Note 2 - New Accounting Standards	9 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Accounting Standards Update and Change in Accounting Principle [Text Block]	2. New Accounting Standar Accounting Standards Updates Adopted In February 2016, 2016 02 842 December 15, 2018 first June 30, 2020. Accounting Standards Updates to Become Effective in Future Periods In November 2018, 2018 18, 808 808 606, 606. December 15, 2019, Other accounting standards that have been issued or proposed by FASB that do not not not not

Note 3 - Loss Per Share

Note 3 - Loss Per Share	9 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	3. Loss per Share Basic and diluted earnings (loss) per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding and does not 31, 2020 2019, not Securities not March 31, 2020 2019, March 31, 2020 2019 Series B preferred stock 59 59 Common stock warrants 6,080 6,080 Common stock options 4,367 3,925 Total potential dilutive securities 10,506 10,064

Note 4 - Inventory

Note 4 - Inventory	9 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventory Inventory consisted of the following at March 31, 2020 June 30, 2019 ( March 31, June 30, 2020 2019 Raw materials $ 369 $ 333 Work in process 198 166 Finished goods 13 31 Total inventory, current $ 580 $ 530 March 31, June 30, 2020 2019 Enriched barium, non-current $ 116 $ 117 Raw materials, non-current 10 38 Total inventory, non-current $ 126 $ 155 Inventory, non-current represents raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will not August 25, 2017, 130 131 4,000 131. three nine March 31, 2020, no 31 131 March 31, 2020, 894 approximately 60 twelve 834 March 31, 2021 no

Note 5 - Property and Equipment

Note 5 - Property and Equipment	9 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment Property and equipment consisted of the following at March 31, 2020 June 30, 2019 ( March 31, June 30, 2020 2019 Land $ 366 $ 366 Equipment 3,878 3,825 Leasehold improvements 4,143 4,143 Other 1 841 645 Property and equipment 9,228 8,979 Less accumulated depreciation (7,484 ) (7,370 ) Property and equipment, net $ 1,744 $ 1,609 1 not no March 31, 2020 June 30, 2019 $ 207,000

Note 6 - Share-Based Compensati

Note 6 - Share-Based Compensation	9 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	6. Share-Based Compensation The following table presents the share-based compensation expense recognized for stock options during the three March 31, 2020 2019 Three Months 2020 2019 Cost of sales $ 8 $ 9 Research and development expenses 18 18 Sales and marketing expenses 24 22 General and administrative expenses 41 30 Total share-based compensation $ 91 $ 79 The following table presents the share-based compensation expense recognized for stock options during the nine March 31, 2020 2019 Nine Months 2020 2019 Cost of sales $ 24 $ 30 Research and development expenses 56 54 Sales and marketing expenses 73 65 General and administrative expenses 123 120 Total share-based compensation $ 276 $ 269 As of March 31, 2020, $362,000 .85 A summary of stock options within the Company’s share-based compensation plans as of March 31, 2020 Weighted Weighted Average Number of Exercise Contractual Intrinsic As of March 31, 2020 Options Price Term (Years) Value Outstanding 4,367 $ .65 7.18 $ 172 Vested and expected to vest 4,367 $ .65 7.18 $ 172 Vested and exercisable 2,800 $ .75 6.42 $ 63 There were 262,500 6,900 $83,000 $1,000 three March 31, 2020 2019, There were no 25,000 $0 $7,000 three March 31, 2020 2019, There were 21,250 10,000 three March 31, 2020 2019, There were no three March 31, 2020 2019, There were 262,500 6,900 $83,000 $1,000 nine March 31, 2020 2019, There were 40,000 262,500 $14,000 $94,000 nine March 31, 2020 2019, There were 29,500 20,000 nine March 31, 2020 2019, There were 26,250 70,750 nine March 31, 2020 2019,

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	9 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Isotope Purchase Agreement In December 2015, 131 one 131. March 31, 2017, December 2016 December 31, 2017. October 23, 2017, 131 December 31, 2018. December 24, 2018, December 31, 2019 131. 131 May 31, 2019. July 11, 2019, August 4, 2019. July 30, 2019, August 2019 December 2020 131

Note 8 - Leases

Note 8 - Leases	9 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. Leases The Company maintains a production facility located at Applied Process Engineering Laboratory (APEL) in Richland, Washington. The APEL facility became operational in September 2007. 15,000 2015, 2017 April 30, 2021, twelve six July 2019, April 20, 2026, April 2020, eighteen $40,000 May 1, 2022. 842 July 1, 2019, $1.2 April 2024 $20,000. 6% not March 31, 2020 4.1 6% For the three nine March 31, 2020, $73,000 $220,000, March 31, 2020 ( Year Ending June 30, 2020 (remaining three months of the year) $ 72 2021 290 2022 290 2023 290 2024 237 Total 1,179 Less: Imputed Interest (117 ) Total Lease Liability 1,062 Less current portion (232 ) Non-current Lease Liability $ 830 Asset Retirement Obligation The Company has an asset retirement obligation (ARO) associated with the facility it currently leases. In connection with the lease modification executed in July 2019, Nine months ended March 31, 2020 2019 Beginning balance $ 621 $ 590 Accretion of discount 22 23 Gain on change in ARO estimate due to lease modification (73 ) - Ending Balance $ 570 $ 613 In July 2019, five $704,000, 5.1% $555,000, $73,000. $73,000.

Note 9 - Shareholders' Equity

Note 9 - Shareholders' Equity	9 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Shareholders’ Equity On March 31, 2020, 3.0% March 31, 2020, not On July 11, 2018, 11,000,000 $0.75, $8.25 $0.75 In a concurrent private placement, the Company sold to each Investor, at no 50% 5,500,000 $0.75 January 11, 2019 January 11, 2024 ( 330,000 $0.9375, January 11, 2019 July 10, 2023, The aggregate number of shares of our common stock issuable upon the exercise of the Warrants is 5,830,000

Note 10 - Contracts With Custom

Note 10 - Contracts With Customers	9 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	10. Contracts with Customers We routinely enter into agreements with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms, and in most cases, prices for the products that we offer. However, these agreements do not no not not not not not Revenues for all products are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no Sources of Revenue We have identified the following revenues disaggregated by revenue source: 1. Domestic – direct sales of products and services. 2. International – direct sales of products and services. During the three March 31, 2020 2019, not During the nine March 31, 2020, not nine March 31, 2019. For the three March 31, 2020 84% 16% 88% 12%, three March 31, 2019. For the nine March 31, 2020 87% 13% 88% 12%, nine March 31, 2019. Contract Balances We incur obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate. Warranty Our general product warranties do not not Returns Generally, we allow returns if not may 50% Significant Judgments in the Application of the Guidance in ASC 606 There are no Commissions and Contract Costs We expense commissions on orders to our sales team upon satisfaction of our performance obligations. We generally do not Practical Expedients Our payment terms for sales direct to customers and distributors are substantially less than the one Shipping and Handling Charges Fees charged to customers for shipping and handling of products are included as revenue and the costs for shipping and handling of products are included as a component of cost of sales. Taxes Collected from Customers As our products are used in another service and are exempt, to this point we have not Concentration of Customers One group of customers, facilities or physician practices has revenues that aggregate to greater than 10% 10% no 10% one Nine Months Ended March 31, Facility 2020 revenue 2019 revenue El Camino, Los Gatos, & other facilities 25.00 % 20.97

Note 3 - Loss Per Share (Tables

Note 3 - Loss Per Share (Tables)	9 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	March 31, 2020 2019 Series B preferred stock 59 59 Common stock warrants 6,080 6,080 Common stock options 4,367 3,925 Total potential dilutive securities 10,506 10,064

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	9 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, June 30, 2020 2019 Raw materials $ 369 $ 333 Work in process 198 166 Finished goods 13 31 Total inventory, current $ 580 $ 530
Schedule of Inventory, Noncurrent [Table Text Block]	March 31, June 30, 2020 2019 Enriched barium, non-current $ 116 $ 117 Raw materials, non-current 10 38 Total inventory, non-current $ 126 $ 155

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, June 30, 2020 2019 Land $ 366 $ 366 Equipment 3,878 3,825 Leasehold improvements 4,143 4,143 Other 1 841 645 Property and equipment 9,228 8,979 Less accumulated depreciation (7,484 ) (7,370 ) Property and equipment, net $ 1,744 $ 1,609

Note 6 - Share-Based Compensa_2

Note 6 - Share-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2020
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months 2020 2019 Cost of sales $ 8 $ 9 Research and development expenses 18 18 Sales and marketing expenses 24 22 General and administrative expenses 41 30 Total share-based compensation $ 91 $ 79 Nine Months 2020 2019 Cost of sales $ 24 $ 30 Research and development expenses 56 54 Sales and marketing expenses 73 65 General and administrative expenses 123 120 Total share-based compensation $ 276 $ 269
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Weighted Weighted Average Number of Exercise Contractual Intrinsic As of March 31, 2020 Options Price Term (Years) Value Outstanding 4,367 $ .65 7.18 $ 172 Vested and expected to vest 4,367 $ .65 7.18 $ 172 Vested and exercisable 2,800 $ .75 6.42 $ 63

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	9 Months Ended
	Mar. 31, 2020
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending June 30, 2020 (remaining three months of the year) $ 72 2021 290 2022 290 2023 290 2024 237 Total 1,179 Less: Imputed Interest (117 ) Total Lease Liability 1,062 Less current portion (232 ) Non-current Lease Liability $ 830
Schedule of Change in Asset Retirement Obligation [Table Text Block]	Nine months ended March 31, 2020 2019 Beginning balance $ 621 $ 590 Accretion of discount 22 23 Gain on change in ARO estimate due to lease modification (73 ) - Ending Balance $ 570 $ 613

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation (Details Textual) xbrli-pure in Thousands	9 Months Ended
	Mar. 31, 2020
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%

Note 3 - Loss Per Share - Antid

Note 3 - Loss Per Share - Antidilutive Securities (Details) - shares shares in Thousands	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive securities (in shares)	10,506	10,064
Series B Preferred Stock [Member]
Antidilutive securities (in shares)	59	59
Warrant [Member]
Antidilutive securities (in shares)	6,080	6,080
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	4,367	3,925

Note 4 - Inventory - Current In

Note 4 - Inventory - Current Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Jun. 30, 2019
Raw materials	$ 369	$ 333
Work in process	198	166
Finished goods	13	31
Total inventory, current	$ 580	$ 530

Note 4 - Inventory - Noncurrent

Note 4 - Inventory - Noncurrent Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Jun. 30, 2019
Total inventory, non-current	$ 126	$ 155
Enriched Barium Inventory [Member]
Total inventory, non-current	116	117
Raw Materials [Member]
Total inventory, non-current	$ 10	$ 38

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details Textual) - USD ($)	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2019
Depreciation, Total	$ 113,000	$ 100,000
Other [Member]
Depreciation, Total	0
Construction in Progress [Member]
Capitalized Costs Related to Advance Planning and Design Work	$ 207,000		$ 207,000

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands		Mar. 31, 2020	Jun. 30, 2019
Property and equipment, gross		$ 9,228	$ 8,979
Less accumulated depreciation		(7,484)	(7,370)
Property and equipment, net		1,744	1,609
Land [Member]
Property and equipment, gross		366	366
Equipment [Member]
Property and equipment, gross		3,878	3,825
Leasehold Improvements [Member]
Property and equipment, gross		4,143	4,143
Other [Member]
Property and equipment, gross	[1]	$ 841	$ 645
[1]	Includes plant and equipment not placed in service which are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore, no depreciation expense has been recognized. Also included at December 31, 2019 and June 30, 2019 are costs associated with advance planning and design work on the Company’s new production facility of $207,000.

Note 6 - Share-Based Compensa_3

Note 6 - Share-Based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 362,000		$ 362,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			310 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)	262,500	6,900	262,500	6,900
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 83,000	$ 1,000	$ 83,000	$ 1,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period (in shares)	0	25,000	40,000	262,500
Share-based Compensation Arrangement By Share-based Payment Award Options Grants in Period Fair Value	$ 0	$ 7,000	$ 14,000	$ 94,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period (in shares)	21,250	10,000	29,500	20,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)	0	0	26,250	70,750

Note 6 - Share-Based Compensa_4

Note 6 - Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Share-based compensation	$ 91	$ 79	$ 276	$ 269
Cost of Sales [Member]
Share-based compensation	8	9	24	30
Research and Development Expense [Member]
Share-based compensation	18	18	56	54
Selling and Marketing Expense [Member]
Share-based compensation	24	22	73	65
General and Administrative Expense [Member]
Share-based compensation	$ 41	$ 30	$ 123	$ 120

Note 6 - Share-Based Compensa_5

Note 6 - Share-Based Compensation - Summary of Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares
Outstanding (in shares) | shares	4,367
Outstanding, weighted exercise price (in dollars per share) | $ / shares	$ 0.65
Outstanding, weighted average contractual term (Year)	7 years 65 days
Outstanding, intrinsic value | $	$ 172
Vested and expected to vest, Options (in shares) | shares	4,367
Vested and expected to vest, weighted exercise price (in dollars per share) | $ / shares	$ 0.65
Vested and expected to vest, weighted average contractual term (Year)	7 years 65 days
Vested and expected to vest, intrinsic value | $	$ 172
Vested and exercisable (in shares) | shares	2,800
Vested and exercisable, weighted exercise price (in dollars per share) | $ / shares	$ 0.75
Vested and exercisable, weighted average contractual term (Year)	6 years 153 days
Vested and exercisable, intrinsic value | $	$ 63

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Details Textual)	1 Months Ended
	Dec. 31, 2015
Purchase Agreement Period (Year)	1 year

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	1 Months Ended		3 Months Ended		9 Months Ended
	Apr. 30, 2024USD ($)	Jul. 31, 2019USD ($)	Mar. 31, 2020USD ($)ft²	Mar. 31, 2019USD ($)	Mar. 31, 2020USD ($)ft²	Mar. 31, 2019USD ($)	Jul. 01, 2019USD ($)	Jun. 30, 2019USD ($)
Operating Lease, Right-of-Use Asset			$ 1,059,000		$ 1,059,000
Operating Lease, Weighted Average Discount Rate, Percent			6.00%		6.00%
Operating Lease, Weighted Average Remaining Lease Term (Year)			4 years 36 days		4 years 36 days
Operating Lease, Expense			$ 73,000		$ 220,000
Lessee, Operating Lease, Renewal Term (Year)		5 years
ARO Original Obligation Amount		$ 704,000
ARO Discount Amount Interest Rate		510.00%
Asset Retirement Obligation, After Adjustment		$ 555,000
Gain (Loss) on Change in ARO Estimate		$ 73,000			73,000
Forecast [Member]
Termination of Lease, Penalty	$ 20,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset							$ 1,200,000
Operating Lease, Weighted Average Discount Rate, Percent							6.00%
Maximum [Member]
Operating Lease Arrangement, Maximum Early Termination Penalty			$ 40,000		$ 40,000
Applied Process Engineering Laboratory [Member]
Area of Real Estate Property (Square Foot) | ft²			15,000		15,000

Note 8 - Leases - Future Operat

Note 8 - Leases - Future Operating Lease Payments and Lease Liability (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Jun. 30, 2019
2020 (remaining three months of the year)	$ 72
2021	290
2022	290
2023	290
2024	237
Total	1,179
Less: Imputed Interest	(117)
Total Lease Liability	1,062
Less current portion	(232)
Non-current Lease Liability	$ 830

Note 8 - Leases - Asset Retirem

Note 8 - Leases - Asset Retirement Obligation (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Beginning balance	$ 621,000			$ 621,000	$ 590,000
Accretion of discount				22,000	23,000
Gain on change in ARO estimate due to lease modification	$ (73,000)			(73,000)
Ending Balance		$ 570,000	$ 613,000	$ 570,000	$ 613,000

Note 9 - Shareholders' Equity (

Note 9 - Shareholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Mar. 31, 2020	Jul. 11, 2018	Mar. 31, 2020	Mar. 31, 2019
Proceeds from Issuance of Common Stock				$ 7,370
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		5,830,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		11,000,000
Shares Issued, Price Per Share (in dollars per share)		$ 0.75
Proceeds from Issuance of Common Stock		$ 8,250
Payments of Stock Issuance Costs		$ 750
Class of Warrant Or Right, Authorized, Percentage		50.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		5,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.75
Oppenheimer & Co [Member]
Sale of Stock, Commission Rate	3.00%
H.C. Wainwright & Co., LLC [Member] | Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		330,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.9375

Note 10 - Contracts With Cust_2

Note 10 - Contracts With Customers (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Restocking Fee, Percentage	50.00%		50.00%
Prostate Brachytherapy [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage	84.00%	88.00%	87.00%	88.00%
Product and Service, Other [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage	16.00%	12.00%	13.00%	12.00%
Geographic Distribution, Foreign [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total	$ 0	$ 0